Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia

NCT07369154 is registered in ClinicalTrials.gov with LB Pharmaceuticals Inc. as lead sponsor.

NCT NCT07369154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07369154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
Lead sponsor
LB Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
April 23, 2026
Completion date
April 30, 2029
Enrollment
900 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia